Table 1 Clinical and biochemical characteristics and use of medications of the study cohort stratified by cancer status
| Â | Patients without cancer | Patients with cancer | Â |
|---|---|---|---|
(n = 5,832) | (n = 271) | ||
| Â | Median (IQRa) or % ( n) | Median (IQRa) or % ( n) | P |
Baseline variables | Â | Â | Â |
Age (years) | 57 (20) | 66 (15) | <0.0001b |
Male gender | 45.8% (2,669) | 51.3% (139) | 0.0743c |
Employment status | Â | Â | <0.0001c |
 Full-time | 33.1% (1,928) | 17.7% (48) |  |
 Housewife | 28.6% (1,665) | 28.8% (78) |  |
 Retired | 27.9% (1,628) | 46.5% (126) |  |
 Others | 10.5% (611) | 7.0% (19) |  |
Smoking status | Â | Â | <0.0001c |
 Ex-smoker | 15.10% (878) | 18.7% (38) |  |
 Current smoker | 14.8% (862) | 23.2% (47) |  |
Alcohol drinking status | Â | Â | <0.0001c |
 Ex-drinker | 11.8% (688) | 21.0% (51) |  |
 Current drinker | 7.3% (427) | 7.4% (20) |  |
Body mass index (kg/m2) | 24.8 (4.9) | 24.3 (4.7) | 0.1296b |
Duration of diabetes (years) | 6 (9) | 8 (10) | 0.0202b |
Glycated hemoglobin HbA1c (%) | 7.2 (2.0) | 7.4 (2.3) | 0.3586b |
Systolic BP (mmHg) | 134 (27) | 137 (25) | 0.0011b |
Diastolic BP (mmHg) | 75 (14) | 75 (16) | 0.6152b |
Glycated hemoglobin (%) | 7.2 (2.0) | 7.4 (2.3) | 0.3586b |
LDL-C (mmol/L) | 3.10 (1.23) | 3.10 (1.30) | 0.8872b |
HDL-C (mmol/L) | 1.26 (0.43) | 1.25 (0.51) | 0.3846b |
Triglyceride (mmol/L) | 1.34 (1.02) | 1.23 (0.77) | 0.0014b |
Total cholesterol (mmol/L) | 5.10 (1.33) | 5.00 (1.42) | 0.3083b |
ACR (mg/mmol) | 2.06 (10.47) | 3.45 (14.18) | 0.0023b |
eGFR (ml/min/1.73m2) | 103.1 (41.6) | 98.8 (37.3) | 0.0184b |
Prior myocardial infarction | 2.0% (114) | 2.6% (7) | 0.4683d |
Prior stroke | 4.5% (261) | 3.7% (10) | 0.5396c |
Death (all-cause) during follow-up | 6.3% (369) | 50.2% (163) | <0.0001c |
Use of medications 2.5 years prior to enrolment | Â | Â | Â |
 Statins | 15.5% (903) | 10.3% (28) | 0.0211c |
 Fibrates | 4.5% (261) | 3.3% (9) | 0.3664c |
 ACEIs/ARBs | 29.5% (1,718) | 28.8% (78) | 0.8114c |
 Insulin | 23.9% (1,394) | 25.8% (70) | 4676c |
 Metformin | 56.6% (3,303) | 52.4% (142) | 0.1691c |
 Sulphonylurea | 62.4% (3,640) | 63.5% (172) | 0.7260c |
 TZDs | 0.5% (28) | 0.4% (1) | 0.7949c |
Use of medications during follow-up e | Â | Â | Â |
 Statins | 38.6% (2,249) | 22.5% (61) | <0.0001c |
 Fibrates | 10.2% (595) | 5.9% (16) | 0.0212c |
 ACEIs/ARBs | 57.9% (3,378) | 52.4% (142) | 0.0720c |
 Insulin | 37.7% (2197) | 36.2% (98) | 0.6161c |
 Metformin | 74.5% (4,347) | 63.8% (173) | <0.0001c |
 Sulphonylurea | 71.3% (4,160) | 69.4% (188) | 0.4864c |
 TZDs | 6.8% (398) | 0.7% (2) | <0.0001c |